SUMMARY Deep vein thrombophlebitis (DVT) and pulmonary emboli (PE) have been uncommonly reported manifestations of systemic lupus erythematosus (SLE). This may be partly due to their being masked by other more familiar lesions of the lungs and extremities in SLE. We have identified 17 patients with SLE from a population of 180 being followed up prospectively who had 21 attacks of DVT and/or PE. Of the total of 21 episodes the SLE was considered to be active in 14, inactive in 6, and variable in a patient with recurring phlebitis. The incidence of hyperlipidaemia, smoking history, and use of birth control medication or corticosteroids was no higher in these patients. These clinical findings thus constitute additional features of SLE occurring in about 9% of patients and may be of significance for morbidity and mortality.
Venous syndromes and pulmonary emboli (PE) have not been commonly reported manifestations of SLE. This may in part be due to the masking of the features of these clinical conditions by other more familiar lesions of the lungs and extremities in this disease. In the course of a prospective study of 180 patients with SLE we identified 17 patients who had 21 attacks of a venous syndrome and/or PE. The purpose of this study was to analyse the incidence of these clinical syndromes and their relation to the disease activity of SLE and to assess whether they segregated a distinct subset of patients with SLE.
Materials and methods
Between July 1970 and July 1977, 180 patients have been followed up prospectively at the Lupus Clinic at the Wellesley Hospital. The standard protocol included both clinical and laboratory evaluation, the latter consisting of complete blood counts, Wester 
Results
Seventeen patients with SLE had 21 attacks of a venous syndrome and/or PE. There were 16 females and 1 male, with a mean age of 36 5 years (range 20-53). All but 3 patients fulfilled 4 or more of the ARA criteria for the classification of SLE.2 Although the remaining 3 patients fulfilled only 3 criteria each, they had other clinical and laboratory features of SLE (Table 1) . Thus, patient 2 had pleurisy, Raynaud's disease, and arthritis, but in addition had proteinuria of 675 mg per 24 hours, a positive ANF and low CH50. Patient 8 had pleurisy, arthritis, and a biological false positive test for syphilis, and as well as proteinuria of 750 mg per 24 hours, an abnormal electroencephalograph, raised DNA binding, and low serum complement (both CH50 and C3). Patient 14 had pleurisy, arthritis, and a positive LE test as well as a peripheral neuropathy, raised DNA binding, and low serum complement and hypergammaglobulinaemia. The mean number of ARA criteria in this group of 17 patients was 7. Of the 21 episodes (Table 2) , 5 consisted of a venous syndrome alone, 11 presented a venous syndrome with associated proved PE, and 5 episodes of PE alone. In the latter 5, venous disease was not conclusively ruled out, as 2 had only a unilateral thrombophlebitis occurred in 24 or 4 -6% and was the presenting symptoms in 24 (0 4%). Armaz-Cruz and associates4 found thrombophlebitis in 13 of 108 patients with SLE. Moore and Lutz5 found 3 instances of thrombophlebitis among 21 cases of SLE. Alarcon-Segovia and Osmundson6 described unexplained often recurrent and superficial thrombophlebitis in 5 patients. More recently Peck et al. 7 described thrombophlebitis in 14 of 114 patients with active SLE. Other large series have not discussed this entity.
We have described a group of 17 patients who had 21 attacks of a venous syndrome and/or PE. Of the 21 episodes 16 consisted of a venous syndrome with or without PE. In these 16 episodes the SLE was considered to be active in 12 cases. On the other hand of 5 episodes of PE without an accompanying venous syndrome the SLE was active in only 2. It is therefore likely that venous syndromes are a feature of SLE and that pulmonary emboli result as a complication of it. They might cause both diagnostic and therapeutic confusion, as the symptoms of PE may mimic those of lung lesions due to SLE. This confusion resulted in 6 of the episodes being treated with both corticosteroids and anticoagulants.
Renal vein thrombosis has been reported in 11 patients with SLE.-1 In 5 of these patients renal biopsies showed membranous lesions. More recently a case showing renal vein thrombosis and nephrotic syndrome with focal glomerulonephritis was reported.1" In our series only 1 patient had renal vein thrombosis and nephrotic syndrome. Her renal biopsy showed a membranous lesion. Of the additional 5 patients whose renal tissue was available 2 had focal glomerulonephritis, one with PE alone and the other with a recurrent venous syndrome. Two patients had mesangial involvement, both with a venous syndrome and PE. One patient with PE and a venous syndrome had mesangial sclerosis. None of these patients had any evidence of nephrotic syndrome or renal vein thrombosis. Three of our patients had a circulating anticoagulant detected at the time of the attack. Although the appearance of thromboembolism despite the presence of a circulating anticoagulant has been previously reported,12 it remains to be explained. In addition, in 3 patients partial thromboplastin times were found to be lower than in controls at the time of venous syndromes and/or PE. It is possible that in these patients a hypercoagulable state was present. However, specific testing for antithrombin deficiency was not carried out.
These 17 patients did not differ in frequency of hyperlipidaemia, smoking, or intake of birth control medications from the remainder of our group of 163 patients with SLE who did not have such episodes. Fewer patients were taking steroids and acetylsalicylic acid at the time of the episode.
There were no other distinguishing clinical features or laboratory and serological variables in this group of patients. Thus the presence of venous syndrome with or without PE did not preselect a specific subset of patients. These clinical findings therefore constitute additional features of SLE or their complications, occurring in about 9 % of patients, which may be of significance for morbidity and mortality. 
